• About Us
    • Overview
    • Senior Team
    • Board of Non-Executive Directors
    • Investors & Shareholders
  • Our Technology
  • Pipeline
  • NephroScan®
  • News & Events
    • Press Releases
    • In the News
    • Events
    • Publications
  • Careers
  • Contact
  • Menu Menu

News & Events

Read the latest news and event updates from Ariceum

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

6 February 2025

Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2025-02-06 08:30:592025-02-06 07:56:42U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

14 January 2025

Berlin, Germany, 14 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC).

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2025-01-14 14:00:012025-01-14 13:56:48FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

13 January 2025

Berlin, Germany / Garching / Munich, January 13, 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of a supply agreement for non-carrier-added (n.c.a.) Actinium-225 (Ac-225) to support the development of Ariceum’s novel targeted radiopharmaceutical therapies (RPT) pipeline, including lead radiopharmaceutical drug, satoreotide for the treatment of aggressive, difficult-to-treat cancers.

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2025-01-13 13:00:322025-01-13 13:01:16Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics

10 January 2025

Berlin, Germany, 10 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the appointment of David Schilansky as Chief Financial Officer with immediate effect, taking over from Rainer Sturm, who will ensure a smooth transition. David has more than 25 years of professional experience, mainly in the pharma and biotech industry, with a strong track-record in company scale-up and fundraising, including on Nasdaq.

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2025-01-10 08:31:152025-01-10 08:32:30David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

11 December 2024

Berlin, Germany, and Beloit, Wisconsin, 11 December 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a supply agreement for the therapeutic medical radioisotope, Actinium-225 (Ac-225).

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2024-12-11 08:30:332024-12-11 08:11:14Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

5 December 2024

Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, today announced the signing of a global supply agreement for the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177).

Read more
https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg 0 0 futurum https://ariceum-therapeutics.com/wp-content/uploads/2022/04/Ariceum_Logo_Web_290px.svg futurum2024-12-05 08:30:342024-12-05 08:30:34Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Page 1 of 512345

© Ariceum Therapeutics

Website by FisherPaul

  • Imprint
  • Privacy Policy

Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.